(Q43874762)

27 November 2017

title

Decision making by NICE: examining the influences of evidence, process and context (English)

1 reference

27 November 2017

1 reference

2

Martin Knapp

1 reference

27 November 2017

Karin H Cerri

1

1 reference

27 November 2017

José-Luis Fernández

series ordinal

3

1 reference

27 November 2017

publication date

21 May 2013

1 reference

Health Economics, Policy and Law

27 November 2017

published in

1 reference

27 November 2017

volume

9

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

119-141

1 reference

Creative Commons Attribution 3.0 Unported

27 November 2017

copyright license

start time

21 May 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Priority setting for health technology assessment. Theoretical considerations and practical approaches. Priority setting Subgroup of the EUR-ASSESS Project

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

An analysis of NICE's 'restricted' (or 'optimized') decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

Public funding of new cancer drugs: Is NICE getting nastier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

10 years of NICE: still growing and still controversial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

Decision-making in priority setting for medicines--a review of empirical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

Has NICE been nice to cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

International diffusion of new health technologies: a ten-country analysis of six health technologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

Interpretation of cost-effectiveness analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

Access to drugs for cancer: Does where you live matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

7 January 2021

Decision makers’ views on health care objectives and budget constraints: results from a pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

7 January 2021

How much are health-care systems prepared to pay to produce a QALY?

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

7 January 2021

Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

7 January 2021

The use of economic evaluation in health care: Australian decision makers' perceptions

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

7 January 2021

“Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

7 January 2021

Review of NICE's recommendations, 1999-2005.

1 reference

https://api.crossref.org/works/10.1017%2FS1744133113000030

7 January 2021

10.1017/S1744133113000030

Identifiers

DOI

1 reference

27 November 2017

1 reference